苏州大学附属第二医院
Second Affiliated Hospital of Soochow University
在本站收录的 61 种疾病中,这家医院列在其中 17 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
苏州大学附属第二医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 鼻咽癌Nasopharyngeal carcinoma5 篇牵头论文
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma4 篇牵头论文
- 胃癌Stomach cancer32 篇牵头论文
- 肺癌Lung cancer64 篇牵头论文牵头 1 项开放试验
- 胰腺癌Pancreatic cancer11 篇牵头论文
- 乳腺癌Breast cancer27 篇牵头论文牵头 1 项开放试验
- 胶质瘤Glioma44 篇牵头论文
- 骨肉瘤Osteosarcoma13 篇牵头论文
- 胃肠道间质瘤Gastrointestinal stromal tumour1 篇牵头论文
- 尤文肉瘤Ewing sarcoma2 篇牵头论文
- 多发性骨髓瘤Multiple myeloma2 篇牵头论文
- 淋巴瘤Lymphoma10 篇牵头论文牵头 3 项开放试验
- 法布雷病Fabry disease0 篇牵头论文
- 杜氏肌营养不良Duchenne muscular dystrophy0 篇牵头论文
- 白塞病Behçet disease1 篇牵头论文
- IgA 肾病IgA nephropathy1 篇牵头论文
- 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文
未列出的收录疾病:肝细胞癌、肝母细胞瘤、视网膜母细胞瘤、脊索瘤、神经母细胞瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、冠心病、先天性心脏病、脊柱侧弯、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、庞贝病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
鼻咽癌
Nasopharyngeal carcinoma2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 2 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。
这些数字背后的记录
牵头的论文5
- Antitumor/anti-inflammatory effects/tissue healing as an all-in-one therapeutic strategy for nasopharyngeal carcinoma.
- First report of opportunistic screening for nasopharyngeal carcinoma by gastroscopy.
- Preliminary study on the correlation between thyroid magnetic resonance parameters and radiation dose after radiotherapy for nasopharyngeal carcinoma.
- Difference after radiotherapy observed in patients with nasopharyngeal carcinoma.
- T1-2N1M0 nasopharyngeal carcinoma chemotherapy or not: A retrospective study.
PubMed 以外找到的论文(未计入)3
- Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma
- Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase
- Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 4 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。
这些数字背后的记录
牵头的论文4
- Characterization of tertiary lymphoid structure identifies competitive binding of CD40 and STING with TRAF2 driving IRF4-mediated B cell activation in esophageal squamous cell carcinoma.
- Involvement of circRNA Regulators MBNL1 and QKI in the Progression of Esophageal Squamous Cell Carcinoma.
- Impact of the extent of recurrent laryngeal nerve lymphadenectomy on thoracic esophageal squamous cell carcinoma: a real-world multicentre study.
- Silencing FAM135B enhances radiosensitivity of esophageal carcinoma cell.
PubMed 以外找到的论文(未计入)2
- 305P Safety and efficacy of endoscopic resection followed by adjuvant chemoradiotherapy (ERACT) for organ preservation in early-stage oesophageal squamous cell carcinoma with high-risk features: A prospective, multicenter, phase II clinical
- Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 32 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
苏州有 4 家医院列在胃癌下全国有 211 家医院列在胃癌下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
- 分期
- 不分期
- 开始
- 2026-06
- 发布
- 登记号
- NCT07552402
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南宁、大连、成都、杭州、武汉、石家庄、福州、苏州、银川
- 正在招募Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- 分期
- III期
- 开始
- 2025-02
- 发布
- 登记号
- NCT06731478
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、厦门、合肥、哈尔滨、天津、太原、常州、徐州、杭州、武汉、沈阳、济南、福州、苏州、西安、郑州、银川
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文32
- Machine learning models for prediction of lymph node metastasis in patients with gastric cancer: a Chinese single-centre study with external validation in an Asian American population.
- Development and current status of anti-reflux esophagogastrostomy after proximal gastrectomy: a literature review.
- Development and Characterization of the [177Lu]Lu-Labeled Anti-CDH17 Nanobody Derivative for Radioimmunotherapy in the Gastric Cancer Xenograft Model.
- Postoperative hypotension in gastric cancer patients: causes and clinical approaches.
- Metabolic regulation of amino acids provides an important basis for individualized nutritional therapy for patients with gastric cancer during the perioperative period.
- Incidence and risk of remnant gastric cancer after gastrectomy for gastric cancer: a population-based study from the SEER database.
- A case-series study of hepatic left lateral segment inversion for surgical field exposure in laparoscopic gastrectomy.
- Tumor-derived Prevotella intermedia aggravates gastric cancer by enhancing Perilipin 3 expression.
- DDX24 promotes tumor progression by mediating hexokinase-1 induced glycolysis in gastric cancer.
- MiR-30a-5p isoform -1|1 promotes the progression of gastric cancer by inhibiting TMEM66 and reducing intratumoral cytotoxic T cells.
- Investigating MATN3 and ASPN as novel drivers of gastric cancer progression via EMT pathways.
- CircFNTA promotes tumorigenesis and progression of gastric cancer via miR-604/miR-647/SCN8A axis.
- The relationship between splenic dose and radiation-induced lymphopenia.
- RAI2 acts as a tumor suppressor with functional significance in gastric cancer.
- High expression of serine protease 2 (PRSS2) associated with invasion, metastasis, and proliferation in gastric cancer.
- Decreased KLF3 Expression via miR-660-5p Targeting Suppresses Gastric Cancer Cell Progression.
- METTL3 regulates N6-methyladenosine modification of ANGPTL3 mRNA and potentiates malignant progression of stomach adenocarcinoma.
- Peripheral CD4+CD25hiCD127low regulatory T cells are increased in patients with gastrointestinal cancer.
- Laparoscopic proximal gastrectomy with right-sided overlap and single-flap valvuloplasty (ROSF): a case-series study.
- Development and validation of a multiphase CT radiomics nomogram for the preoperative prediction of lymphovascular invasion in patients with gastric cancer.
- Exosomal circ_0091741 promotes gastric cancer cell autophagy and chemoresistance via the miR-330-3p/TRIM14/Dvl2/Wnt/β-catenin axis.
- MST4 as a novel therapeutic target for autophagy and radiosensitivity in gastric cancer.
- Targeting ROR1 inhibits glucocorticoid-induced gastric cancer growth.
- Inhibition of Musashi-1 enhances chemotherapeutic sensitivity in gastric cancer patient-derived xenografts.
- PRaG Therapy of Refractory Metastatic Gastric Cancer: A Case Report.
- Current status of internal hernia after gastrectomy for gastric cancer.
- Clinicopathological Analysis and Prognostic Assessment of TCN1 in Patients with Gastric Cancer.
- Current status of laparoscopic proximal gastrectomy in proximal gastric cancer: Technical details and oncologic outcomes.
- TYMSOS drives the proliferation, migration, and invasion of gastric cancer cells by regulating ZNF703 via sponging miR-4739.
- Mast1 mediates radiation-induced gastric injury via the P38 MAPK pathway.
- Esophagus two-step-cut overlap method in esophagojejunostomy after laparoscopic gastrectomy.
- UFBP1, a key component in ufmylation, enhances drug sensitivity by promoting proteasomal degradation of oxidative stress-response transcription factor Nrf2.
中文论文(未计入)4
- [Application status of vagus nerve preservation and double-flap technique in laparoscopic proximal gastrectomy].
- [Artificial intelligence for lymph node metastasis prediction in gastric cancer: research progress].
- [A preliminary exploration of reduced port laparoscopic proximal gastrectomy with right-sided overlap and single-flap valvuloplasty (ROSF)].
- [Immune-Related Pancreatitis Caused by Immune Checkpoint Inhibitor Nivolumab:Report of One Case].
它在 ClinicalTrials.gov 上的全部试验(任何状态)10
- Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
- Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- HFNO Combined With NPA Reduces Hypoxia During Sedated Gastrointestinal Endoscopy In Obese Patients
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
- Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
- Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
- HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
- A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
- Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center Study
癌症
肺癌
Lung cancer2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 64 篇,占 0.3%。
苏州有 3 家医院列在肺癌下全国有 251 家医院列在肺癌下
这家医院参与的开放试验 3
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 即将招募The Impact of Thoracic Paravertebral Nerve Block At Different Positions on Pain Relief in Patients Undergoing Single-Port Thoracoscopic Partial Lung Resection
- 分期
- 不分期
- 开始
- 2025-01
- 发布
- 登记号
- NCT06789276
年龄 18 岁 至 70 岁(登记的条件)
牵头:苏州大学附属第二医院苏州
- 正在招募Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- 分期
- I/II期
- 开始
- 2023-04
- 发布
- 登记号
- NCT05786924
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 4 家列出的医院为研究中心上海、北京、济南、苏州
- 即将招募YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
- 分期
- III期
- 开始
- 2023-05
- 发布
- 登记号
- NCT05767892
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、北京、南京、南昌、厦门、台州、合肥、呼和浩特、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、洛阳、济南、石家庄、福州、苏州、蚌埠、西安、郑州、重庆、长沙、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文64
- A combined model integrating radiomics and deep learning based on multiparametric magnetic resonance imaging for classification of brain metastases.
- A Neovascularization and EGFR Dual-Targeting Gold Nanotheranostic System for Non-Small Cell Lung Cancer Treatment.
- Distinct CTC Specific RNA Profile Enables NSCLC Early Detection and Dynamic Monitoring of Advanced NSCLC.
- Lymphocyte-to-C-reactive protein ratio predicts prognosis in unresectable locally advanced non-small cell lung cancer patients.
- Feasibility and mechanism of 68Ga-FAPI PET/CT in monitoring chemoresistance of non-small cell lung cancer.
- MicroRNA-486: a dual-function biomarker for diagnosis and tumor immune microenvironment characterization in non-small cell lung cancer.
- The mechanism of E3 ubiquitin ligase HERC1 regulating ferroptosis in lung adenocarcinoma cells.
- IGF2BP3 Triggers STAT3 Pathway by Stabilizing SRC RNA in an m6A-Dependent Manner to Promote Lymphatic Metastasis in LUAD.
- NADH:ubiquinone oxidoreductase core subunit S8 expression and functional significance in non-small cell lung cancer.
- Mitochondrial carrier homolog 2 is important for mitochondrial functionality and non-small cell lung cancer cell growth.
- Expression patterns of MCM8 in lung adenocarcinoma and its correlation with key biological processes.
- Risk factors and intraoperative identification of non-lepidic predominant lung adenocarcinoma presenting as subsolid nodule: A multicenter study.
- Suppressor of Tumorigenicity 14 inhibits non-small cell lung cancer cell proliferation by suppressing Transketolase O-GlcNAcylation.
- Radiomics based on dual-layer spectral detector CT for predicting EGFR mutation status in non-small cell lung cancer.
- Prognostic implications, genomic and immune characteristics of lung adenocarcinoma with lepidic growth pattern.
- Targeting the lung tumour stroma: harnessing nanoparticles for effective therapeutic interventions.
- TRANS: a prediction model for EGFR mutation status in NSCLC based on radiomics and clinical features.
- Which descriptor should spread through air spaces (STAS) be incorporated into? T descriptor versus residual tumor classification.
- Comparison of lung lesion assessment using free-breathing dynamic contrast-enhanced 1.5-T MRI with a golden-angle radial stack-of-stars VIBE sequence and CT.
- Keratin 6A (KRT6A) promotes radioresistance, invasion, and metastasis in lung cancer via p53 signaling pathway.
- Elevated origin recognition complex subunit 6 expression promotes non-small cell lung cancer cell growth.
- Ectopic Expression of TIGIT in Lung Adenocarcinoma and Its Clinical Significance.
- 2.5D deep learning based on multi-parameter MRI to differentiate primary lung cancer pathological subtypes in patients with brain metastases.
- CXCL5 impedes CD8+ T cell immunity by upregulating PD-L1 expression in lung cancer via PXN/AKT signaling phosphorylation and neutrophil chemotaxis.
- Lipid alterations play a role in the integration of PD-1/PD-L1 inhibitors and anlotinib for the treatment of advanced non-small-cell lung cancer.
- Tislelizumab combined with GT chemotherapy for intimal sarcoma of inferior vena cava: A case report.
- GIMAP7 inhibits epithelial-mesenchymal transition and glycolysis in lung adenocarcinoma cells via regulating the Smo/AMPK signaling pathway.
- Identification of epithelial-mesenchymal transition-related biomarkers in lung adenocarcinoma using bioinformatics and lab experiments.
- POLRMT over-expression is linked to WNT/beta-catenin signaling, immune infiltration, and unfavorable outcomes in lung adenocarcinoma patients.
- Clinical implications and molecular features of tertiary lymphoid structures in stage I lung adenocarcinoma.
- FDW028, a novel FUT8 inhibitor, impels lysosomal proteolysis of B7-H3 via chaperone-mediated autophagy pathway and exhibits potent efficacy against metastatic colorectal cancer.
- Clinical profiles and intraoperative identification of complex glands in stage I lung adenocarcinoma.
- CYFIP2 serves as a prognostic biomarker and correlates with tumor immune microenvironment in human cancers.
- EUS-guided ethanol ablation for management of lung carcinoma (with video).
- Identification of WD-Repeat Protein 72 as a Novel Prognostic Biomarker in Non-Small-Cell Lung Cancer.
- Sarcopenia as a Determinant of the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: A Meta-Analysis.
- Plasma metabolomics for the assessment of the progression of non-small cell lung cancer.
- Characteristics and risk factors for advanced lung cancer with pulmonary embolism: A cross-sectional, case-control study.
- Characterization of TCF-1 and its relationship between CD8+ TIL densities and immune checkpoints and their joint influences on prognoses of lung adenocarcinoma patients.
- Oncogenic zinc finger protein ZNF687 accelerates lung adenocarcinoma cell proliferation and tumor progression by activating the PI3K/AKT signaling pathway.
- Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib.
- Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study.
- Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 and Its Related Molecules as Potential Biomarkers in Small-Cell Lung Cancer.
- Roles of DNA polymerase ζ in the radiotherapy sensitivity and oxidative stress of lung cancer cells.
- Comment on "clinicopathological features, survival outcomes, and appropriate surgical approaches for stage I acinar and papillary predominant lung adenocarcinoma".
- Targeting sphingosine kinase 1/2 by a novel dual inhibitor SKI-349 suppresses non-small cell lung cancer cell growth.
- Image classification of immune checkpoint inhibitor-related pneumonia in lung cancer patients.
- Identification of the mitochondrial protein ADCK2 as a therapeutic oncotarget of NSCLC.
- Log odds of positive lymph nodes is a robust predictor of survival and benefits from postoperative radiotherapy in stage IIIA-N2 resected non-small cell lung cancer.
- Potentiated lung adenocarcinoma (LUAD) cell growth, migration and invasion by lncRNA DARS-AS1 via miR-188-5p/ KLF12 axis.
- LncRNA LOC100129620 promotes osteosarcoma progression through regulating CDK6 expression, tumor angiogenesis, and macrophage polarization.
- Overexpression of hsa_circ_0002874 promotes resistance of non-small cell lung cancer to paclitaxel by modulating miR-1273f/MDM2/p53 pathway.
- Characterization of Extracapsular Lymph Node Involvement and Its Clinicopathological Characteristics in Stage II-IIIA Lung Adenocarcinoma.
- ASO Author Reflections: Old Song, New Sung-Extracapsular Extension in Lung Cancer in the Era of Eighth-Edition N Classification.
- Stromal-derived miR-486-5p promotes metastasis of non-small-cell lung cancer cells by targeting the CADM1/tight junctions axis in vascular endothelial cells.
- The requirement of mitochondrial RNA polymerase for non-small cell lung cancer cell growth.
- M2 macrophage-derived exosomal long non-coding RNA AGAP2-AS1 enhances radiotherapy immunity in lung cancer by reducing microRNA-296 and elevating NOTCH2.
- Clinical implications of the pattern of recurrence of pN2 non-small-cell lung cancer.
- MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.
- FUCA2 Is a Prognostic Biomarker and Correlated With an Immunosuppressive Microenvironment in Pan-Cancer.
- Differentiation of pulmonary sclerosing pneumocytoma from solid malignant pulmonary nodules by radiomic analysis on multiphasic CT.
- Letter to the Editor: Clinical Implications of Postoperative Radiotherapy on Patient Survival in Stage IIIA Resected Lung Cancer: More Variables Should Be Considered.
- Characterization of CD66b and its relationship between immune checkpoints and their synergistic impact in the prognosis of surgically resected lung adenocarcinoma.
- A novel GHR-ALK fusion gene in a patient with metastatic lung adenocarcinoma and its response to crizotinib: a case report.
中文论文(未计入)5
- [Radiotherapy Combined with Immunotherapy and Chemotherapy Improves Prognosis and Demonstrates Synergistic Effects in Extensive-stage Small Cell Lung Cancer].
- [Efficacy Analysis of High-flow Nasal Oxygen Therapy in Patients Accepting Single-port Video-assisted Thoracoscopic Lobectomy].
- [Progress in Single-cell RNA Sequencing of Lung Adenocarcinoma].
- [Clinicopathological and genetic features of metastatic lung cancer to the adrenal glands: report of four cases].
- [Differential diagnosis of pure ground glass nodules in lung with spectral CT imaging].
它在 ClinicalTrials.gov 上的全部试验(任何状态)14
- The Impact of Thoracic Paravertebral Nerve Block At Different Positions on Pain Relief in Patients Undergoing Single-Port Thoracoscopic Partial Lung Resection
- A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer
- Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)
- Preoperative and Postoperative ctDNA Comparison in Early Stage Lung Cancer
- YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
- Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
- Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
- Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
- A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC
- Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer
- Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)
- Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer
癌症
胰腺癌
Pancreatic cancer2021–2025 年中国大陆作者发表的 5,743 篇胰腺癌 PubMed 英文论文中,这家医院牵头了 11 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
苏州有 2 家医院列在胰腺癌下全国有 192 家医院列在胰腺癌下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases
- 分期
- I期
- 开始
- 2024-01
- 发布
- 登记号
- NCT06278454
年龄 18 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、天津、苏州、郑州、重庆
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文11
- GALNT4-induced O-GalNAc glycosylation of MUC1 accelerates the invasive phenotype of PDAC.
- A Phase I/II Study Protocol of a Novel Neoadjuvant 'PRaG' Regimen (Radiotherapy, GM-CSF, and Cadonilimab) with AG Chemotherapy to Improve Resectability in Locally Advanced Pancreatic Ductal Adenocarcinoma: The NeoPRAG Study.
- The impact of the muscle mass-to-fat ratio on the prognosis of patients undergoing pancreaticoduodenectomy for pancreatic cancer.
- Macroscopic on-site magnifier-based evaluation to estimate visible tissue core cut-off lengths using EUS-FNA with 22-gauge needles.
- YAP-LAMB3 axis dictates cellular resistance of pancreatic ductal adenocarcinoma cells to gemcitabine.
- PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma: A case report.
- Identification of matrix-remodeling associated 5 as a possible molecular oncotarget of pancreatic cancer.
- EUS-guided ethanol ablation for management of lung carcinoma (with video).
- Individualized prognostic signature for pancreatic carcinoma validated by integrating immune-related gene pairs (IRGPs).
- Elevated expression of nuclear receptor-binding SET domain 3 promotes pancreatic cancer cell growth.
- Hepatobiliary and Pancreatic: Endoscopic resection of biliary ductal tumour.
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
- Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases
- Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
- Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
癌症
乳腺癌
Breast cancer2021–2025 年中国大陆作者发表的 16,974 篇乳腺癌 PubMed 英文论文中,这家医院牵头了 27 篇,占 0.2%。
苏州有 2 家医院列在乳腺癌下全国有 219 家医院列在乳腺癌下
这家医院参与的开放试验 4
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC
- 分期
- 不分期
- 开始
- 2024-02
- 发布
- 登记号
- NCT06235931
年龄 65 岁 至 未注明;仅女性(登记的条件)
牵头:苏州大学附属第二医院苏州
- 正在招募JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
- 分期
- III期
- 开始
- 2023-12
- 发布
- 登记号
- NCT06079983
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 60 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、大连、天津、太原、安阳、广州、徐州、成都、新乡、昆明、杭州、梅州、武汉、汕头、沈阳、洛阳、济南、湛江、石家庄、福州、苏州、衡阳、襄阳、西宁、西安、贵阳、遵义、郑州、重庆、长春、长沙、青岛
- 正在招募A Study of YL202 in Selected Patients With Advanced Solid Tumors
- 分期
- II期
- 开始
- 2023-12
- 发布
- 登记号
- NCT06107686
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、乌鲁木齐、北京、南宁、南昌、台州、合肥、哈尔滨、太原、广州、徐州、成都、杭州、桂林、梅州、武汉、汕头、沈阳、济南、潍坊、苏州、襄阳、西安、郑州、重庆、长春、长沙、青岛
- 邀请入组A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
- 分期
- II期
- 开始
- 2025-08
- 发布
- 登记号
- NCT07376629
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 22 家列出的医院为研究中心上海、临沂、南京、厦门、合肥、哈尔滨、天津、太原、安阳、广州、徐州、成都、杭州、武汉、沈阳、济南、福州、苏州、西安、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文27
- Radiological-pathological correlation in encapsulated papillary carcinoma of the breast.
- Circ_0057582 inhibits breast cancer progression via hnRNPF/YAP/SOX9 axis and M2 polarization in TAMs by autophagic degradation of ISG15.
- Collagen Hydrogel Loaded With 9-cisRA-Lip Is an Option for Treatment of Secondary Lymphedema after Surgery.
- Hyaluronic acid and polyvinyl alcohol-based radioresponsive hydrogel for combined radioimmunotherapy of breast cancer bone metastasis.
- Study on Heparanase Promoting Breast Cancer Cell Proliferation and Inhibiting NK Cell Cytolytic Activity Via the PD-1/PD-L1 Pathway.
- Development and validation of a novel sodium-overload related genes signature for prognostic prediction in breast cancer: integrating bioinformatics and experimental approaches.
- Igniting tumour microenvironment in triple-negative breast cancer using a mannose/hyaluronic acid dual-coated Ganoderma polysaccharide-superparamagnetic iron oxide nanocomplex for combinational therapies.
- Innovative applications of visualized thermosensitive color-changing personalized boluses in post-mastectomy radiotherapy: a dosimetric analysis.
- Leucine rich repeat containing 15 promotes triple-negative breast cancer proliferation and invasion via the ITGB1/FAK/PI3K signalling pathway.
- A novel SERS-lateral flow assay (LFA) tray for monitoring of miR-155-5p during pyroptosis in breast cancer cells.
- The novel circRNA circ_0045881 inhibits cell proliferation and invasion by targeting mir-214-3p in triple-negative breast cancer.
- A comprehensive evaluation of circ_0065214/ miR-188-3p/GPNMB axis in breast cancer.
- Exosomal miR-122-3p represses the growth and metastasis of MCF-7/ADR cells by targeting GRK4-mediated activation of the Wnt/β-catenin pathway.
- SNHG14 promotes triple-negative breast cancer cell proliferation, invasion, and chemoresistance by regulating the ERK/MAPK signaling pathway.
- Metabolism-regulating non-coding RNAs in breast cancer: roles, mechanisms and clinical applications.
- LINC01929 Is a Prognostic Biomarker for Multiple Tumours and Promotes Cell Proliferation in Breast Cancer Through the TNF/STAT3 Axis.
- Letter to the editor regarding "Association between gout and subsequent breast cancer: a retrospective cohort study including 67,598 primary care patients in Germany".
- Tumor-promoting mechanisms of macrophage-derived extracellular vesicles-enclosed microRNA-660 in breast cancer progression.
- HOXD9 transcriptionally induced UXT facilitate breast cancer progression via epigenetic modification of RND3.
- KLF14 alleviated breast cancer invasion and M2 macrophages polarization through modulating SOCS3/RhoA/Rock/STAT3 signaling.
- LINC00680 modulates docetaxel resistance in breast cancer via the miR-320b/CDKL5 axis.
- A novel prognostic model associated with the overall survival in patients with breast cancer based on lipid metabolism-related long noncoding RNAs.
- CTCF-Induced lncRNA C5orf66-AS1 Facilitates the Progression of Triple-Negative Breast Cancer via Sponging miR-149-5p to Up-Regulate CTCF and CTNNB1 to Activate Wnt/β-Catenin Pathway.
- Transcription factor KLF2 enhances the sensitivity of breast cancer cells to cisplatin by suppressing kinase WEE1.
- Lobetyolin inhibits the proliferation of breast cancer cells via ASCT2 down-regulation-induced apoptosis.
- The role of ferroptosis-related genes for overall survival prediction in breast cancer.
- B7-H3 on breast cancer cell MCF7 inhibits IFN-γ release from tumour-infiltrating T cells.
它在 ClinicalTrials.gov 上的全部试验(任何状态)9
- A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC
- Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)
- A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
- A Study of YL202 in Selected Patients With Advanced Solid Tumors
- JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
- PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
- A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer
- Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer
- Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer
癌症
胶质瘤
Glioma2021–2025 年中国大陆作者发表的 7,081 篇胶质瘤 PubMed 英文论文中,这家医院牵头了 44 篇,占 0.6%。
- 牵头的开放试验
- 0
- 正在或即将招募
苏州有 4 家医院列在胶质瘤下全国有 187 家医院列在胶质瘤下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Study of GC101 TIL in Brain Glioma (Soochow2)
- 分期
- 早期I期
- 开始
- 2021-05
- 发布
- 登记号
- NCT04943913
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心苏州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文44
- Selenoprotein P drives glioma malignancy via LRP8-dependent activation of Wnt/β-catenin signaling.
- Procollagen C-protease enhancer protein promotes glioma growth by activating ERK signaling.
- MDA-9/Syntenin promotes glioma cell proliferation and invasion via exosome-mediated activation of the PI3K-AKT signaling pathway.
- FDX1 facilitates elesclomol-induced cuproptosis and promotes glioblastoma development via transcription factor NFKB1.
- KIF4A Promotes Glioblastoma Malignant Progression and Transmission of Temozolomide Resistance in the Tumor Microenvironment via the HIF1A/VEGFA Axis.
- Amlodipine synergizes with temozolomide against glioma stem cells by modulating MGMT expression through downregulation of the AKT/GSK3β/β-catenin axis.
- SRBD1 Regulates the Cell Cycle, Apoptosis, and M2 Macrophage Polarization via the RPL11-MDM2-p53 Pathway in Glioma.
- The miR-192/EGR1-HOXB9 loop inhibits immune evasion in glioma by arresting their NSC phenotypes.
- The miR-192-EGR1/HOXB9 Loop Regulates Glioma Cell Stemness and Malignant Phenotypes by Promoting Their Mesenchymal Transition.
- KIF4A Inhibits Ferroptosis in Glioblastoma via the CHMP4B/GPX4 Axis and Promotes Temozolomide Resistance.
- KRT80, Regulated by RNF8-Mediated Ubiquitination, Contributes to Glucose Metabolic Reprogramming and Progression of Glioblastoma.
- Immuno-oncological interactions between meningeal lymphatics and glioblastoma: from mechanisms to therapies.
- Transformed astrocytes confer temozolomide resistance on glioblastoma via delivering ALKBH7 to enhance APNG expression after educating by glioblastoma stem cells-derived exosomes.
- Efficacy and safety of anlotinib combined with the STUPP regimen in patients with newly diagnosed glioblastoma: a multicenter, single-arm, phase II trial.
- Glioma stem cell-derived exosomes induce the transformation of astrocytes via the miR-3065-5p/DLG2 signaling axis.
- SENP1-Mediated deSUMOylation Regulates the Tumor Remodeling of Glioma Stem Cells Under Hypoxic Stress.
- Interferon-γ inducible protein 30 promotes the epithelial-mesenchymal transition-like phenotype and chemoresistance by activating EGFR/AKT/GSK3β/β-catenin pathway in glioma.
- Exosomal miR-6733-5p mediates cross-talk between glioblastoma stem cells and macrophages and promotes glioblastoma multiform progression synergistically.
- Upregulation of the ZNF148/PTX3 axis promotes malignant transformation of dendritic cells in glioma stem-like cells microenvironment.
- RNA-binding protein DHX9 promotes glioma growth and tumor-associated macrophages infiltration via TCF12.
- Exosome-Mediated Transfer of circ-GLIS3 Enhances Temozolomide Resistance in Glioma Cells Through the miR-548m/MED31 Axis.
- LILRB2-containing small extracellular vesicles from glioblastoma promote tumor progression by promoting the formation and expansion of myeloid-derived suppressor cells.
- LncRNA SPRY4-IT1 facilitates cell proliferation and angiogenesis of glioma via the miR-101-3p/EZH2/VEGFA signaling axis.
- The FDX1 methylation regulatory mechanism in the malignant phenotype of glioma.
- PA2G4P4 Promotes Glioma Cell Migration and Tumorigenesis through the PTEN/AKT/mTOR Signaling Pathway.
- HDAC1 mediates epithelial-mesenchymal transition and promotes cancer cell invasion in glioblastoma.
- YME1L overexpression exerts pro-tumorigenic activity in glioma by promoting Gαi1 expression and Akt activation.
- Rare adult pilocytic astrocytoma of the septum pellucidum with novel RIN2::BRAF fusion.
- Molecular characteristics of single patient-derived glioma stem-like cells from primary and recurrent glioblastoma.
- MEOX2-mediated regulation of Cathepsin S promotes cell proliferation and motility in glioma.
- RIT1 Promotes Glioma Proliferation and Invasion via the AKT/ERK/NF-ĸB Signaling Pathway.
- TM4SF1 promotes glioma malignancy through multiple mechanisms.
- GBP3 promotes glioblastoma resistance to temozolomide by enhancing DNA damage repair.
- Gliosarcoma with osteosarcomatous component: A case report and short review illustration.
- Nicardipine sensitizes temozolomide by inhibiting autophagy and promoting cell apoptosis in glioma stem cells.
- A retrospective analysis of the risk factors affecting recurrence time in patients with recurrent glioblastoma.
- Integrative analysis of TP73 profile prognostic significance in WHO grade II/III glioma.
- Circ_0001367 inhibits glioma proliferation, migration and invasion by sponging miR-431 and thus regulating NRXN3.
- GBP5 drives malignancy of glioblastoma via the Src/ERK1/2/MMP3 pathway.
- Do the combination of multiparametric MRI-based radiomics and selected blood inflammatory markers predict the grade and proliferation in glioma patients?
- FHL1 promotes glioblastoma aggressiveness through regulating EGFR expression.
- Doxorubicin Delivered via ApoE-Directed Reduction-Sensitive Polymersomes Potently Inhibit Orthotopic Human Glioblastoma Xenografts in Nude Mice.
- Self‑renewal signaling pathways and differentiation therapies of glioblastoma stem cells (Review).
- Bioinformatics analysis reveals a stem cell-expressed circ-Serpine2-mediated miRNA-mRNA regulatory subnetwork in the malignant progression of glioma.
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 13 篇,占 0.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 14 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文13
- STUB1-mediated ubiquitination of SLC25A10 regulates mitochondrial function and drives osteosarcoma progression: A novel therapeutic target.
- KAT7 serves as an oncogenic gene and regulates CCL3 expression via STAT1 signaling in osteosarcoma.
- Relationship between surgical compliance and survival outcome in patients with Ewing sarcoma.
- Mitochondria targeted biomimetic platform for chemo/photodynamic combination therapy against osteosarcoma.
- A Feedback Loop of LINC00665 and the Wnt Signaling Pathway Expedites Osteosarcoma Cell Proliferation, Invasion, and Epithelial-Mesenchymal Transition.
- ADCK1 is a potential therapeutic target of osteosarcoma.
- Identification of Gαi3 as a promising target for osteosarcoma treatment.
- Gliosarcoma with osteosarcomatous component: A case report and short review illustration.
- LncRNA LOC100129620 promotes osteosarcoma progression through regulating CDK6 expression, tumor angiogenesis, and macrophage polarization.
- COL3A1 and Its Related Molecules as Potential Biomarkers in the Development of Human Ewing's Sarcoma.
- ARHGEF3 Associated with Invasion, Metastasis, and Proliferation in Human Osteosarcoma.
- miRNA-296-5p functions as a potential tumor suppressor in human osteosarcoma by targeting SND1.
- Propofol suppresses osteosarcoma cell function by regulating FOXO1/TUSC7.
早期论文(2016–2020 年)9
- MicroRNA-187 suppresses the proliferation migration and invasion of human osteosarcoma cells by targeting MAPK7.
- High Expression of N-Acetylgalactosaminyl-transferase 1 (GALNT1) Associated with Invasion, Metastasis, and Proliferation in Osteosarcoma.
- Proliferation inhibition and apoptosis promotion by dual silencing of VEGF and Survivin in human osteosarcoma.
- EP1 receptor is involved in prostaglandin E2-induced osteosarcoma growth.
- TCF3-activated LINC00152 exerts oncogenic role in osteosarcoma through regulating miR-1182/CDK14 axis.
- Long noncoding RNA SNHG6 promotes osteosarcoma cell proliferation through regulating p21 and KLF2.
- MiR-299-5p targets cell cycle to promote cell proliferation and progression of osteosarcoma.
- The anti-tumor effect of pachymic acid on osteosarcoma cells by inducing PTEN and Caspase 3/7-dependent apoptosis.
- miR-29 Family Inhibits Resistance to Methotrexate and Promotes Cell Apoptosis by Targeting COL3A1 and MCL1 in Osteosarcoma.
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 7 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。
癌症
尤文肉瘤
Ewing sarcoma2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 3 家医院列在尤文肉瘤下全国有 134 家医院列在尤文肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.1%。
- 牵头的开放试验
- 0
- 正在或即将招募
苏州有 2 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下
这家医院参与的开放试验 3
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- 分期
- I期
- 开始
- 2026-05
- 发布
- 登记号
- NCT07477587
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛
- 正在招募A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
- 分期
- I期
- 开始
- 2025-12
- 发布
- 登记号
- NCT07179679
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、南京、南充、南昌、广州、承德、苏州、西安、重庆
- 正在招募UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
- 分期
- 不分期
- 开始
- 2024-04
- 发布
- 登记号
- NCT06279026
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心苏州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文2
中文论文(未计入)5
- [The Role and Possible Mechanism of T Cell Costimulatory Molecule CD28 Activation in Pathogenesis of Multiple Myeloma].
- [The Impact of SRSF1 -Mediated Alternative Splicing of RBBP6 on the Proliferation of Multiple Myeloma Cells].
- [Bone Marrow Adipocytes Promote the Survival of Multiple Myeloma Cells and Up-Regulate Their Chemoresistance].
- [Clinical Significance of CD28 Expression in Newly Diagnosed Multiple Myeloma].
- [Effect of the Connexin 43 Coupling to the Biobehavior of Multiple Myeloma Cells].
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
- Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
- Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
- UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
- A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects
- Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma
血液疾病
淋巴瘤
Lymphoma2021–2025 年中国大陆作者发表的 3,830 篇淋巴瘤 PubMed 英文论文中,这家医院牵头了 10 篇,占 0.3%。
苏州有 2 家医院列在淋巴瘤下全国有 199 家医院列在淋巴瘤下
这家医院参与的开放试验 6
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma.
- 分期
- 早期I期
- 开始
- 2026-06
- 发布
- 登记号
- NCT07598578
年龄 18 岁 至 75 岁(登记的条件)
牵头:苏州大学附属第二医院苏州
- 正在招募Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study
- 分期
- II期
- 开始
- 2025-06
- 发布
- 登记号
- NCT07002099
年龄 18 岁 至 未注明(登记的条件)
牵头:苏州大学附属第二医院苏州
- 即将招募Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL
- 分期
- 不分期
- 开始
- 2024-02
- 发布
- 登记号
- NCT06289959
年龄 18 岁 至 未注明(登记的条件)
牵头:苏州大学附属第二医院苏州
- 正在招募A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
- 分期
- I/II期
- 开始
- 2025-07
- 发布
- 登记号
- NCT07124936
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 19 家列出的医院为研究中心北京、南宁、南昌、太原、广州、成都、昆明、杭州、武汉、沈阳、济南、福州、苏州、西安、郑州、长春、长沙
- 正在招募Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- 分期
- III期
- 开始
- 2024-05
- 发布
- 登记号
- NCT06521255
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、乌鲁木齐、北京、南昌、天津、广州、成都、杭州、武汉、济南、温州、苏州、郑州、重庆、长春、长沙
- 正在招募A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
- 分期
- I期
- 开始
- 2024-08
- 发布
- 登记号
- NCT06615193
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 8 家列出的医院为研究中心南昌、天津、徐州、杭州、济南、苏州、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文10
- Circulating tumor DNA from blood and cerebrospinal fluid in DLBCL: simultaneous evaluation of mutations, IG rearrangement, and IG clonality.
- Glofitamab treatment of Richter transformation with isolated central nervous system involvement: a case report.
- An anti-CD19-exosome delivery system navigates the blood-brain barrier for targeting of central nervous system lymphoma.
- Combined Inhibition of XPO1 and DNA Methylation Exerts Synergistic Effects in DLBCL.
- A novel cancer-associated fibroblast-related gene signature for predicting diffuse large B cell lymphoma prognosis using weighted gene co-expression network analysis and machine learning.
- A promising natural product in diffuse large B-cell lymphoma therapy by targeting PIM1.
- Diffuse large B-cell lymphoma-derived exosomes push macrophage polarization toward M2 phenotype via GP130/STAT3 signaling pathway.
- CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma via M2 macrophage interactions: A bioinformatic analysis of the tumor microenvironment.
- EZH2 inhibitor DZNep blocks cell proliferation of GCB-DLBCL cells by upregulating p16.
- piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL.
它在 ClinicalTrials.gov 上的全部试验(任何状态)16
- An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma.
- Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study
- Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL
- Chidamide in Patients With Recurrent and Refractory Diffuse Large b
- A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
- A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
- Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Obinutuzumab in Chinese Real-world Patients With iNHL
- A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .
- TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
- Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
- A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.
- The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies
- A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection
- A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
- A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
其他疾病
法布雷病
Fabry disease2021–2025 年没有牵头法布雷病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 3 家医院列在法布雷病下全国有 80 家医院列在法布雷病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。
其他疾病
杜氏肌营养不良
Duchenne muscular dystrophy2021–2025 年没有牵头杜氏肌营养不良的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 3 家医院列在杜氏肌营养不良下全国有 111 家医院列在杜氏肌营养不良下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。
其他疾病
白塞病
Behçet disease2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 3 家医院列在白塞病下全国有 139 家医院列在白塞病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 6 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
- A Pharmacokinetic Study of Budesonide Delayed Release Tablet D23A (D23) in Healthy Chinese Participants Under Fasting Conditions
- A Food-Effect Study of Budesonide Delayed Release Tablet (D23A) in Healthy Chinese Participants
- A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
其他疾病
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
苏州有 4 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
联系这家医院
出示给工作人员或司机的院名卡
苏州大学附属第二医院
Second Affiliated Hospital of Soochow University
苏州
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药